Targeting protein tyrosine phosphatase non-receptor type 6 (PTPN6) as a therapeutic strategy in acute myeloid leukemia
Open Access
- 21 December 2024
- journal article
- research article
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 11
Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid progenitor cells. Despite advancements in treatment, the prognosis for AML patients remains poor, highlighting the need for novel therapeutic targets. Protein Tyrosine Phosphatase Non-Receptor Type 6 (PTPN6), also known as SHP-1, is a critical regulator of hematopoietic cell signaling and has been implicated in various leukemias. This study investigates the therapeutic potential of targeting PTPN6 in AML. We employed both in vitro and in vivo models to evaluate the effects of PTPN6 inhibition on AML cell proliferation, apoptosis, and differentiation. Our results demonstrate that PTPN6 inhibition leads to a significant reduction in AML cell viability, induces apoptosis, and promotes differentiation of leukemic cells into mature myeloid cells. Mechanistic studies revealed that PTPN6 inhibition disrupts key signaling pathways involved in AML pathogenesis, including the JAK/STAT and PI3K/AKT pathways. Furthermore, the combination of PTPN6 inhibitors with standard chemotherapeutic agents exhibited a synergistic effect, enhancing the overall therapeutic efficacy. These findings suggest that PTPN6 is a promising therapeutic target in AML and warrants further investigation into the development of PTPN6 inhibitors for clinical application in AML treatment.Keywords
This publication has 72 references indexed in Scilit:
- The NLRP3 inflammasome drives inflammation in ischemia/reperfusion injury after transient middle cerebral artery occlusion in miceBrain, Behavior, and Immunity, 2021
- miR-211-5p alleviates focal cerebral ischemia-reperfusion injury in rats by down-regulating the expression of COX2Biochemical Pharmacology, 2020
- Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysisCancer Immunology, Immunotherapy, 2019
- Epidemiology of acute myeloid leukemia: Recent progress and enduring challengesBlood Reviews, 2019
- Recent progress in the discovery of myeloid differentiation 2 (MD2) modulators for inflammatory diseasesDrug Discovery Today, 2018
- The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteinsTumor Biology, 2016
- Long Noncoding RNAs in Cancer PathwaysCancer Cell, 2016
- Hepatocyte-Specific Ptpn6 Deletion Promotes Hepatic Lipid Accretion, but Reduces NAFLD in Diet-Induced Obesity: Potential Role of PparγHepatology, 2013
- The tyrosine phosphatase SHP-1 negatively regulates cytotrophoblast proliferation in first-trimester human placenta by modulating EGFR activationCellular and Molecular Life Sciences, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012